What is Bicara Therapeutics's D&A?

Bicara Therapeutics (BCAX) reported D&A of $44K in Q1 2026.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Bicara Therapeutics BCAX D&A

D&A at other companies

Syndax PharmaceuticalsSNDX

$4M—

Aurinia PharmaceuticalsAUPH

$4.82M-0.8%

AmgenAMGN

——

Natera, Inc.NTRA

——

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.68B+81.4%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's D&A?: Bicara Therapeutics (BCAX) reported D&A of $44K in Q1 2026.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.